Document is current
Any future updates will be listed below
-
Authors
Sever, Matjaz
Drozd-Sokolowska, Joanna https://orcid.org/0000-0002-4562-6264
Gras, Luuk
Koster, Linda
Folber, Frantisek https://orcid.org/0000-0001-7034-769X
Mielke, Stephan
Fenk, Roland
Basak, Grzegorz https://orcid.org/0000-0003-3858-8180
Apperley, Jane https://orcid.org/0000-0002-1710-1794
Byrne, Jennifer
Rambaldi, Alessandro https://orcid.org/0000-0002-3739-7502
Ringhoffer, Mark
Eder, Matthias
Trneny, Marek https://orcid.org/0000-0002-6952-6073
Blaise, Didier https://orcid.org/0000-0002-5684-9447
Lenhoff, Stig
Isaksson, Cecilia
Passweg, Jakob https://orcid.org/0000-0001-7092-3351
Partanen, Anu https://orcid.org/0000-0002-5634-2582
Sakellari, Ioanna
Schönland, Stefan https://orcid.org/0000-0002-4853-5579
Morris, Curly
Beksac, Meral
Raj, Kavita https://orcid.org/0000-0002-8258-354X
Hayden, Patrick J. https://orcid.org/0000-0003-1374-4503
McLornan, Donal P. https://orcid.org/0000-0003-1224-091X
- License Information
-
More Information
Article History
Received: 16 June 2024
Revised: 21 October 2024
Accepted: 30 October 2024
First Online: 12 November 2024
Competing interests
: JDS – honoraria AbbVie, Roche, Janssen, Astra Zeneca, SOBI, Takeda, BMS, Novartis, Swixx; Advisory board meetings organized by Janssen-Cilag, Sanofi, AstraZeneca, Roche, BeiGene; AP - honoraria from Behring and Abbvie, participation in scientific Advisory board meetings organized by Abbvie, Janssen-Cilag, Novartis, Pfizer, Sanofi and Takeda; none of COI directly related to the study.
: This retrospective study was approved by the Chronic Malignancies Working Party (CMWP) of the EBMT and was performed in accordance with the Declaration of Helsinki.
